Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions

Am J Respir Crit Care Med. 2015 Feb 1;191(3):252-4. doi: 10.1164/rccm.201411-2044ED.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Idiopathic Pulmonary Fibrosis / drug therapy*
  • Indoles / therapeutic use*
  • Pyridones / therapeutic use*
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Enzyme Inhibitors
  • Indoles
  • Pyridones
  • pirfenidone
  • nintedanib